For Immediate Release
Chicago, IL – September 12, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (
MSFT Quick Quote MSFT - Free Report) , Novo Nordisk A/S ( NVO Quick Quote NVO - Free Report) , Booking Holdings Inc. ( BKNG Quick Quote BKNG - Free Report) , Sony Group Corp. ( SONY Quick Quote SONY - Free Report) and EOG Resources, Inc. ( EOG Quick Quote EOG - Free Report) . Here are highlights from Monday’s Analyst Blog: Top Stock Reports for Microsoft, Novo Nordisk and Booking Holdings
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Novo Nordisk A/S and Booking Holdings Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>> Shares of Microsoft have gained +40.3% over the year-to-date period against the Zacks Computer - Software industry’s gain of +43.3%. The company’s fourth-quarter results benefited from improvement in Intelligent Cloud and Productivity and Business Processes, offset in part by a decline in More Personal Computing. Strong adoption of Office 365 Commercial solutions drove Productivity and Business Processes revenues. Continued momentum in the small and medium businesses and frontline worker offerings, as well as gain in revenue per user drove top-line growth. However, More Personal Computing revenues decreased due to weak Windows and Devices businesses. Steady performance in Talent Solutions aided LinkedIn revenues. However, decline gaming revenues and sluggishness in Azure business have been headwinds. Increasing spend on Azure enhancements amid stiff competition in the cloud space remains a concern. (You can ) read the full research report on Microsoft here >>> Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+45.7% vs. +10.4%). The company has one of the broadest diabetes portfolios in the industry. Ozempic and Rybelsus have been performing well in the market. Saxenda and Wegovy sales have been gaining momentum. Label expansions of diabetes and obesity care drugs will likely further boost sales. Novo Nordisk raised its 2023 view along with its second-quarter results, expecting better sales of its GLP-1 diabetes products. Its diversifying efforts to develop new treatments are encouraging. However, competition is getting stiffer from pharma bigwigs like Pfizer, who are likely to eat away from Novo Nordisk’s Diabetes care market share, due to serious supply constraints in international markets. Patent expiry and pricing pressure across the diabetes market also remain a woe. (You can ) read the full research report on Novo Nordisk here >>> Shares of Booking Holdings have outperformed the Zacks Internet - Commerce industry over the year-to-date period (+56.0% vs. +42.1%). The company is benefiting from a substantial improvement in booking trends driven by growing demand for travel. This, in, turn, is helping lower cancellation rates. Booking Holdings expects room night growth to increase at a low double-digit rate on a year-on-year basis in the third quarter. Solid growth in domestic bookings is driving growth. The company is experiencing solid momentum in international regions, which is a positive. Strong growth in rental cars, airline ticket units and booked room nights is another positive. Solid momentum across the agency, merchant, advertising and other businesses is a tailwind. Further, strengthening alternative accommodation business and flight capabilities are major positives. However, intensifying competition is a headwind. (You can ) read the full research report on Booking Holdings here >>> Other noteworthy reports we are featuring today include Sony Group Corp. and EOG Resources, Inc. Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of
+46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.